
While Genmab remains tight-lipped about its defeat in court over a royalties dispute with partner Janssen, the latter has been a little more outspoken about the expected consequences of the ruling.
”We are proud of our strong partnership and collaboration with Genmab to make a meaningful difference for patients living with multiple myeloma,” Janssen writes in a press release, adding:
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app